GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Earnings per Share (Diluted)

Dova Pharmaceuticals (Dova Pharmaceuticals) Earnings per Share (Diluted) : $-2.61 (TTM As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Earnings per Share (Diluted)?

Dova Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.74. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.61.

Dova Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2019 was $-0.74. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.61.

Dova Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2019 was $-0.74. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 was $-2.61.


Dova Pharmaceuticals Earnings per Share (Diluted) Historical Data

The historical data trend for Dova Pharmaceuticals's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Earnings per Share (Diluted) Chart

Dova Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18
Earnings per Share (Diluted)
- -1.40 -2.60

Dova Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -0.69 -0.58 -0.60 -0.74

Competitive Comparison of Dova Pharmaceuticals's Earnings per Share (Diluted)

For the Biotechnology subindustry, Dova Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dova Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dova Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Dova Pharmaceuticals's PE Ratio falls into.



Dova Pharmaceuticals Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Dova Pharmaceuticals's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2018 is calculated as

Diluted Earnings Per Share (A: Dec. 2018 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-72.282-0)/27.803
=-2.60

Dova Pharmaceuticals's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2019 is calculated as

Diluted Earnings Per Share (Q: Sep. 2019 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-21.285-0)/28.800
=-0.74

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Dova Pharmaceuticals  (NAS:DOVA) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dova Pharmaceuticals Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Executives
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd officer: Chief Medical Officer C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli director, officer: President & CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir director, officer: President & CEO C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707

Dova Pharmaceuticals (Dova Pharmaceuticals) Headlines

From GuruFocus